ALK expression is absent in pancreatic ductal adenocarcinoma
ALK expression is absent in pancreatic ductal adenocarcinoma
复制标题
DOI：
10.1007/s00432-014-1774-4
复制
发表时间：
2014-07
影响因子：
3.6
通讯作者：
S. Ormanns;G. Assmann;S. Reu;E. Gallmeier;Dominik C. Bader;A. Kleespies;M. Haas;S. Kruger;V. Heinemann;T. Kirchner;S. Boeck
中科院分区：
文献类型：
--
作者：
S. Ormanns;G. Assmann;S. Reu;E. Gallmeier;Dominik C. Bader;A. Kleespies;M. Haas;S. Kruger;V. Heinemann;T. Kirchner;S. Boeck
目的胰腺导管腺癌（PDAC）中是否存在间变性淋巴瘤激酶（ALK）的表达尚未明确。方法在一项回顾性研究中，采用组织芯片（TMA）上的特异性ALK检测试剂盒，通过免疫组化（IHC）筛选存档的PDAC手术标本中肿瘤和正常组织中ALK的表达。99名患者中的58名（59%）患有肿瘤阳性疾病，80名患者（81%）患有pT3肿瘤。49例患者接受了R0切除术，48例患者的切除状态被分类为R1。关于ALK表达，5例在TMA上显示微弱的免疫反应性，在整个切片上均为阴性。结论在99例PDAC患者中，免疫组化法均未检测到ALK的表达，ALK可能不是PDAC的相关药物靶点。
PurposeIt has not yet been clearly defined whether anaplastic lymphoma kinase (ALK) expression can be detected in pancreatic ductal adenocarcinoma (PDAC).MethodsWithin a retrospective study, archival PDAC surgical specimens were screened for ALK expression in tumor and normal tissue by immunohistochemistry (IHC) with the use of a specific ALK detection kit on a tissue microarray (TMA).ResultsPDAC tumor tissue was available from 99 resected cases: fifty-eight out of 99 patients (59 %) had nodal-positive disease, and 80 patients (81 %) had pT3 tumors. Forty-nine patients underwent R0 resection, and in 48 cases, resection status was classified R1. Regarding ALK expression, five cases showed faint immunoreactivity on TMA, which was negative on whole mount sections. All other 94 cases showed no ALK expression.ConclusionIn 99 PDAC cases, no ALK expression was detected by IHC; ALK thus may not serve as a relevant drug target in PDAC.